The regulatory body of medicines from India approved the first vaccine Human DNA against him covid-19 in the world for emergency use in the country, according to BBC Mundo.
According to a study provisional cited by the pharmaceutical company india Cadila Healthcare, la vaccine ZyCoV-D of three doses prevented symptomatic disease in the 66% of people vaccinated.
The DNA vaccines Earlier ones worked well in animals, but not in humans.
India has administered more than 570 million doses of three approved vaccines in the country: Covishield, Covaxin y Sputnik V.
Cadila Healthcare Company announced that it carried out the largest clinical trial of the vaccine ZyCoV-D on India with 28,000 volunteers and the third test phase took place at the peak of the second hello of the virus.
In this way, according to the pharmaceutical, the “efficacy of the vaccine against mutant strains“, Especially the Delta variant, known to be highly infectious.
How does this vaccine work?
The ADN and the ARN son basic components of life, indicates the information. They are molecules that carry the Genetic information transmitted from parents to children.
The DNA vaccine, like other vaccines, teaches the immune system from body to fight the virus existing. ZyCoV-D uses small rings of DNA that carry Genetic information cells to produce the “cob protein”, which the covid-19 uses to adhere and enter the human cells, explains BBC World.
This vaccine has the particularity to be administered with a disposable injector needleless, which uses a thin stream of the liquid to penetrate the skin and distribute itself into the tissue.
Currently more than 160 DNA vaccines different in human clinical trials in EE.UU. Most are for the treatment of cancers existing and a third for the treatment of VIH.
Some advantage of the vaccines from ADN They are: cost, which is relatively cheap; their easy transport and storage since they are kept at temperatures between -2 to 8 ° C. On the other hand, among their disadvantages It is that some vaccines of this type developed in the past have presented failures, reducing their effectiveness; as well as the fact that ZyCoV-D requires three doses, instead of two.
–
